Synedgen
Developer of glycomics-based regenerative therapeutics focused on restoring mucosal barrier function. The company advances orally delivered and topical therapeutics from preclinical models into clinic-ready assets, operates a platform for targeted glycomics discovery, reports clinical and preclinical efficacy data (including GI mucosal repair and an oral rinse for xerostomia), and holds funded grants and patent protection for its programs.
Industries
Nr. of Employees
small (1-50)
Patents
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-12594296-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-12465616-B2
View DetailsMethods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View Details
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US-12594296-B2
View DetailsMethods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
US-12465616-B2
View DetailsMethods for treatment or prevention of damage resulting from radiation, trauma or shock
US-11975018-B2
View DetailsProducts
MIIST305
Clinic-ready, orally delivered therapeutic candidate developed to repair gastrointestinal mucosal injury, restore GI function, and reduce inflammation; supported by preclinical efficacy data.
Moisyn oral rinse
Oral rinse product line developed for xerostomia (dry mouth); received U.S. FDA 510(k) clearance and demonstrated symptom improvements in a clinical study.
SYGN305
Drug candidate developed for the treatment of Radiation Mucositis and Radiation Proctitis.
SYGN309
Drug candidate developed for GI Infection.
SYGN313
Drug candidate developed for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD).
SYGN399
Drug candidate developed for Radiation Syndrome.
MIIST305
Clinic-ready, orally delivered therapeutic candidate developed to repair gastrointestinal mucosal injury, restore GI function, and reduce inflammation; supported by preclinical efficacy data.
Moisyn oral rinse
Oral rinse product line developed for xerostomia (dry mouth); received U.S. FDA 510(k) clearance and demonstrated symptom improvements in a clinical study.
SYGN305
Drug candidate developed for the treatment of Radiation Mucositis and Radiation Proctitis.
SYGN309
Drug candidate developed for GI Infection.
SYGN313
Drug candidate developed for both acute and chronic inflammation of the GI tract, such as Crohn’s disease and inflammatory bowel disease (IBD).
SYGN399
Drug candidate developed for Radiation Syndrome.
Expertise Areas
- Glycomics-driven drug discovery
- Mucosal barrier repair and regenerative therapeutics
- Gastrointestinal (GI) therapeutic development
- Oral care therapeutics and xerostomia treatment
Key Technologies
- Glycomics-based discovery
- Oral drug formulation and delivery
- Mucosal barrier restoration mechanisms
- Preclinical murine models
News & Updates
Company announced executive leadership changes naming Dr. Laura Saward CEO and Dr. Kenton Gregory CMO.
Announcement of Gut Microbes publication reporting preclinical data that MIIST305 mitigates gastrointestinal acute radiation syndrome injury in a mouse model.
Company announced the appointment of Dr. Laura Saward as Chief Scientific Officer.
Company received U.S. FDA 510(k) clearance to market Moisyn products for treatment of xerostomia.
EU patent granted covering treatment of gastrointestinal mucositis.
Company announced executive leadership changes naming Dr. Laura Saward CEO and Dr. Kenton Gregory CMO.
Announcement of Gut Microbes publication reporting preclinical data that MIIST305 mitigates gastrointestinal acute radiation syndrome injury in a mouse model.
Company announced the appointment of Dr. Laura Saward as Chief Scientific Officer.
Company received U.S. FDA 510(k) clearance to market Moisyn products for treatment of xerostomia.
EU patent granted covering treatment of gastrointestinal mucositis.